Equillium Past Earnings Performance
Past criteria checks 0/6
Equillium has been growing earnings at an average annual rate of 9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 76.9% per year.
Key information
9.0%
Earnings growth rate
21.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 76.9% |
| Return on equity | -19.9% |
| Net Margin | -10.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Equillium makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 46 | -5 | 13 | 39 |
| 30 Jun 24 | 43 | -8 | 14 | 39 |
| 31 Mar 24 | 38 | -12 | 14 | 38 |
| 31 Dec 23 | 36 | -13 | 14 | 37 |
| 30 Sep 23 | 43 | -8 | 16 | 36 |
| 30 Jun 23 | 34 | -18 | 16 | 36 |
| 31 Mar 23 | 25 | -29 | 17 | 36 |
| 31 Dec 22 | 16 | -62 | 17 | 38 |
| 30 Sep 22 | 0 | -76 | 15 | 37 |
| 30 Jun 22 | 0 | -72 | 13 | 35 |
| 31 Mar 22 | 0 | -67 | 12 | 31 |
| 31 Dec 21 | 0 | -39 | 11 | 26 |
| 30 Sep 21 | 0 | -37 | 11 | 25 |
| 30 Jun 21 | 0 | -34 | 10 | 23 |
| 31 Mar 21 | 0 | -31 | 10 | 21 |
| 31 Dec 20 | 0 | -30 | 10 | 19 |
| 30 Sep 20 | 0 | -28 | 10 | 18 |
| 30 Jun 20 | 0 | -28 | 10 | 18 |
| 31 Mar 20 | 0 | -27 | 9 | 19 |
| 31 Dec 19 | 0 | -26 | 9 | 18 |
| 30 Sep 19 | 0 | -23 | 9 | 15 |
| 30 Jun 19 | 0 | -22 | 7 | 12 |
| 31 Mar 19 | 0 | -18 | 6 | 8 |
| 31 Dec 18 | 0 | -13 | 4 | 5 |
| 30 Sep 18 | 0 | -10 | 2 | 3 |
Quality Earnings: 0FY is currently unprofitable.
Growing Profit Margin: 0FY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0FY is unprofitable, but has reduced losses over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare 0FY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0FY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0FY has a negative Return on Equity (-19.91%), as it is currently unprofitable.